Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
- 30 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5), 843-853
- https://doi.org/10.1007/s00280-020-04061-9
Abstract
Purpose We evaluated the expression of proteasome subunits to assess whether the proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. Methods Cisplatin-resistant (CR) variants were established from three non-small cell lung cancer (NSCLC) cell lines (A549, H1299, and H1975) and two small cell lung cancer (SCLC) cell lines (SBC3 and SBC5). The expression of proteasome subunits, the sensitivity to immunoproteasome inhibitors, and 20S proteasomal proteolytic activity were examined in the CR variants of the lung cancer cell lines. Results All five CR cell lines highly expressed one or both of the immunoproteasome subunit genes, PSMB8 and PSMB9, while no clear trend was observed in the expression of constitutive proteasome subunits. The CR cells expressed significantly higher levels of PSMB8 and PSMB9 proteins, as well. The CR variants of the H1299 and SBC3 cell lines were more sensitive to immunoproteasome inhibitors, and had significantly more proteasomal proteolytic activity than their parental counterparts. Conclusions The immunoproteasome may be an effective therapeutic target in a subset of CR lung cancers. Proteasomal proteolytic activity may be a predictive marker for the efficacy of immunoproteasome inhibitors in cisplatin-resistant SCLC and NSCLC.Keywords
This publication has 43 references indexed in Scilit:
- A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer CellsMolecular Cancer Therapeutics, 2012
- Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cellsCancer Letters, 2012
- Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stressOncogene, 2010
- The immunoproteasome, the 20S proteasome and the PA28αβ proteasome regulator are oxidative-stress-adaptive proteolytic complexesBiochemical Journal, 2010
- The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatinCritical Reviews in Toxicology, 2010
- Cellular Responses to Cisplatin-Induced DNA DamageJournal of Nucleic Acids, 2010
- Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunitsCancer, 2008
- Hydrogen peroxide induces nitric oxide and proteosome activity in endothelial cells: A bell-shaped signaling responseFree Radical Biology & Medicine, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005